Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00630890 · ClinicalTrials.gov registry record · Phase 1
Cyberknife Radiosurgery Boost for Hilar Cholangiocarcinoma (Klatskin Tumor)
A Phase 1 study, sponsored by University of California, San Francisco.
- Terminated
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT00630890 is a Phase 1 study that was terminated before completion, run by University of California, San Francisco. The registered enrollment target is 11 participants.
The verdict
NCT00630890, a Phase 1 study, was terminated before completion, sponsored by University of California, San Francisco.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety of giving external beam radiation, followed by a Cyberknife radiosurgery boost at different dose levels, together with a chemotherapy drug called capecitabine. The dose of Cyberknife radiosurgery boost will be made higher slowly in this protocol. Patients with hilar cholangiocarcinoma (Klatskin tumor), which is not amenable for surgical removal, are eligible. The hypothesis is that highly focused high dose radiation delivered using Cyberknife in conjunction with traditional radiation and chemotherapy can improve outcome in this patient population.
Interventions
- RADIATION External beam radiation and Cyberknife radiosurgery boost and capecitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2007-10 |
| Est. Completion | 2008-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00630890
The ClinicalTrials.gov registry entry for NCT00630890 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which External beam radiation and Cyberknife radiosurgery boost and capecitabine is the first listed.
NCT00630890 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00630890 about?
NCT00630890 is a clinical study titled "Cyberknife Radiosurgery Boost for Hilar Cholangiocarcinoma (Klatskin Tumor)". The purpose of this study is to test the safety of giving external beam radiation, followed by a Cyberknife radiosurgery boost at different dose levels, together with a chemotherapy drug called capecitabine. The dose of Cyberknife radiosurgery boost will be made higher slowly in this protocol. Patie...
What is the current status of trial NCT00630890?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2007-10. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00630890?
The interventions under investigation include: External beam radiation and Cyberknife radiosurgery boost and capecitabine (RADIATION).
Who is sponsoring clinical trial NCT00630890?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.